Payment overview · 2025
General Payments
$1,206.49
61 reported records · 17 companies
Healthcare provider profile · identity verified
Tye B. Young, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · CHATTANOOGA, TN · NPI 1174635957
Verified facts
What the public records show
CMS Open Payments records show Tye B. Young, D.O. received $1,206.49 in general payments during 2025 across 61 reported records.
Lilly USA, LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $206.89 | 17.1% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $185.25 | 15.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.70 | 12.7% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.40 | 6.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.62 | 6.0% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $68.40 | 5.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.70 | 5.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $62.95 | 5.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.53 | 5.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.93 | 4.9% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $44.69 | 3.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.46 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.25 | 2.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.47 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.12 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.48 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.65 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,206.49 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $190.82 | 12 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $185.25 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.70 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $153.70 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $139.04 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.40 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.62 | 4 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $68.40 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $67.70 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.95 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $55.79 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.25 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 77 |
| Omeprazole | Omeprazole | 228 | 79 |
| Losartan Potassium | Losartan Potassium | 193 | 64 |
| Lisinopril | Lisinopril | 183 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 30 |
| Metformin Hcl | Metformin Hcl | 120 | 43 |
| Simvastatin | Simvastatin | 114 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 20 |
| Furosemide | Furosemide | 101 | 33 |
| Gabapentin | Gabapentin | 100 | 39 |
| Trazodone Hcl | Trazodone Hcl | 98 | 37 |
| Metformin Hcl Er | Metformin Hcl | 87 | 27 |
| Valsartan | Valsartan | 85 | 25 |
| Carvedilol | Carvedilol | 80 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 23 |
| Mounjaro | Tirzepatide | 78 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 25 |
| Atenolol | Atenolol | 75 | 24 |
| Sertraline Hcl | Sertraline Hcl | 75 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 23 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Meloxicam | Meloxicam | 66 | 25 |
| Prednisone | Prednisone | 66 | 23 |
| Ozempic | Semaglutide | 63 | 18 |
| Methylprednisolone | Methylprednisolone | 61 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 17 |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 23 |
| Allopurinol | Allopurinol | 54 | 20 |
| Lorazepam | Lorazepam | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 17 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Estradiol | Estradiol | 43 | 14 |
| Eliquis | Apixaban | 41 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 16 |
| Meclizine Hcl | Meclizine Hcl | 40 | 17 |
| Finasteride | Finasteride | 39 | 13 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Spironolactone | Spironolactone | 38 | 14 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Potassium Chloride | Potassium Chloride | 37 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | 17 |
| Glimepiride | Glimepiride | 35 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | 13 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Famotidine | Famotidine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Diazepam | Diazepam | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,206.49 · 61 records | Lilly USA, LLC | Auvelity, CAPLYTA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INCEPTIV, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, REXULTI, Rybelsus, SKYCLARYS, The Cologuard Plus Collection Kit, VENASEAL, VIBERZI, VRAYLAR, Veozah, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error